Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 02, 2018 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx to Hold First Quarter 2018 Financial Results Conference Call on Wednesday, May 9, 2018

MOUNTAIN VIEW, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that the Company's first quarter 2018 financial results will be released after market...
April 11, 2018 16:05 ET | Source: ChemoCentryx, Inc.

ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting

MOUNTAIN VIEW, Calif., April 11, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced the presentation of positive safety, efficacy and quality of life results from the...
April 03, 2018 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx to Present at Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two...
March 22, 2018 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS)

-- Peer-reviewed findings show blocking CCR2 provides rapid and sustained renal benefit in well-established models of FSGS -- -- Improvements in renal function with CCR2 inhibition associated with...
March 09, 2018 07:00 ET | Source: ChemoCentryx, Inc.

ChemoCentryx Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Highlights

-- Phase III ADVOCATE trial of avacopan in treatment of ANCA vasculitis nears 75% of patient enrollment target as European Medicine Agency continues review process of Conditional Marketing...
March 06, 2018 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx to Present at the Cowen and Company 38th Annual Health Care Conference

MOUNTAIN VIEW, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the...
March 01, 2018 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx to Hold Fourth Quarter 2017 Financial Results Conference Call on Friday, March 9, 2018

MOUNTAIN VIEW, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that the Company's fourth quarter 2017 financial results will be released before market...
January 22, 2018 17:00 ET | Source: ChemoCentryx, Inc.

ChemoCentryx Announces Positive Overall Survival Results with CCR2 Inhibitor CCX872 for Locally Advanced/Metastatic Pancreatic Cancer

-- CCX872 plus FOLFIRINOX resulted in overall survival of 29 percent at 18 months in all patients -- -- Clinical findings to be presented at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium -- ...
January 08, 2018 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx Strengthens Senior Executive Team with the Appointment of William Fairey as Executive Vice President and Chief Operating Officer

MOUNTAIN VIEW, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases...
January 04, 2018 07:05 ET | Source: ChemoCentryx, Inc.

ChemoCentryx Secures up to $100 Million in New Capital Commitments

-- ChemoCentryx to Receive $50 Million Milestone from Vifor Pharma for Validation of Conditional Marketing Authorization Application for Avacopan for the Treatment of ANCA Vasculitis -- -- Company...